Letter From the Editors
Are We Prepared for the Genomics Era?
By J. Lyle Bootma
Are You Ready For Some Ethics, Some Success, Some Cytoprotectants, and Some New Board Members?
By Daniel D. Von Hoff, MD, FACP, and J. Lyle Bootman, PhD
Lymphomas – The Diseases That Taught Us Monoclonal Antibodies Can Work
Right Tool, Right Time, Right Reason
By J. Lyle Bootman, PhD, and Daniel D. Von Hoff, MD, FACP
Letter to the Editor
AGGRAVATION OF SCHIZOPHRENIA BY CLOMIPRAMINE IN A PATIENT WITH COMORBID OBSESSIVE-COMPULSIVE DISORDER
LETTER TO THE EDITOR
GLUCOSE TESTING IN PATIENTS RECEIVING ANTIPSYCHOTIC
Lineamientos universales
Indíce de medicamentos para Latinoamérica
Long-Term Antidepressant Treatment
By Katia K. Delrahim, BA, Rachel Maddux, BA, and Mark Hyman Rapaport, MD
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder
By Richard C. Josiassen, John M. Kane, Grace S. Liang, Joshua Burke, Christopher F. O’Brien
Long-Term Treatment Strategies in Affective Disorders
By Martin B. Keller, MD
Long-Term Treatment Strategies in Anxiety Disorders
By Christer Allgulander, MD, Robert M. A. Hirschfeld, MD, and David J. Nutt, MD, PhD
Major (ICD-10) Depression Inventory
Management of Aggressive Lymphoma
By Koen van Besien, MD, and Katarzyna Finiewicz, MD
Management of Late-Life Depression: Focus on Comorbid Conditions
By Warren D. Taylor, MD, and K. Ranga Rama Krishnan, MB, ChB
Managing Deep Vein Thrombosis Risk in Oncology Patients Office and Outpatient Settings
MODERATOR: Brian A. Meltzer, MD, MBA
DISCUSSANTS: Leo R. Zacharski, MS, MD, and Steven R. Deitcher, MD
Maternal and Fetal Outcomes After Lamotrigine Use in Pregnancy: A Retrospective Analysis from an Urban Maternal Mental Health Centre in New Zealand
By Chandni Prakash, Susan Hatters-Friedman, Charmian Moller-Olsen, Abigail North
Mechanism of Action of Antidepressants
By Francesc Artigas, PhD, David J. Nutt, MD, PhD, and Richard Shelton, MD